Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 3:36 PM ET

Life Sciences Tools and Services

Company Overview of Crown Bioscience, Inc.

Company Overview

Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...

3375 Scott Boulevard

Suite 108

Santa Clara, CA 95054

United States

Founded in 2006





Key Executives for Crown Bioscience, Inc.

Co-Founder and Chief Executive Officer
Age: 51
Executive Chairman
Chief Financial Officer
Age: 50
Senior Vice President of Operation and General Manager of Crownbio Taicang Facility
Compensation as of Fiscal Year 2015.

Crown Bioscience, Inc. Key Developments

Crown Bioscience Offers Unique Immuno-Oncology Translational Research Platform

Crown Bioscience provides a comprehensive immuno-oncology translational research platform. Crown’s suite of in vitro and in vivo immuno-oncology assays employing translational experimental models help inform and accelerate the development of cancer immunotherapies and move the best candidates forward to clinical trials. Crown’s in vitro immuno-oncology assays, including immunophenotyping and immuno-functional assays, help scientists validate immuno-oncology targets, screen for immuno-modulating agents, understand mechanisms of actions and identify biomarkers. With one of the world’s large collections of validated in vivo syngeneic cell line models, as well as primary allografts of tumors, Crown helps scientists evaluate and understand novel anticancer compounds. Crown also provides various humanized immuno-oncology in vivo models, including the MiXeno™ platform of transient human immunity by mixing human peripheral blood mononucleated cells (PBMC) with xenograft models for testing human biological-based immunotherapeutics for cancers, providing a simple, cost-effective alternative to full hematopoietic stem cell reconstitution. Crown’s other humanized immuno-oncology technologies under development include HuGEMM with knocked-in human checkpoint targets, e.g., huPD1 and huCTLA4, into immunocompetent models and PDX in human hematopoietic stem reconstituted models, both of which will be extremely valuable in evaluating human biologicals for immunotherapies.

Crown Bioscience Inc. Announces Executive Appointments

Crown Bioscience Inc. named Tetsuya Totsuka, Ph.D. as manager of business development for Japan. Before joining Crown Bioscience, Totsuka was director and COO of business development for a Tokyo-based biotech firm and director of the original developer of disparity mutagenesis technology for the improvement and breeding of useful organisms, including microorganisms, cultured cells, plants and animals. Mayet Pantastico will be the director of business development for Australia, Singapore, New Zealand and Korea. With more than 14 years of experience in sales and business development in the pharmaceutical industry, she was most recently sales and marketing manager in the Asia-Pacific region for a preclinical CRO focused on oncology models and GLP toxicology studies.

Crown Bioscience Enters an Exclusive Preclinical Services Alliance Utilizing the Collection of Naturally Occurring Diabetic Translational Models

Crown Bioscience announced that it has entered an exclusive preclinical services alliance utilizing the collection of naturally occurring diabetic translational models. The models are designed for research involving cardiovascular and metabolic diseases, including spontaneous developed diabetes and its complications, such as diabetic nephropathy, left ventricular diastolic dysfunction, fatty liver, diet-induced dyslipidemia, etc. They were developed to mirror aspects of human disease related to obesity, nephropathy, hyperglycemia, hyperinsulinemia, dyslipidemia, glucose intolerance, reduced glucose disposition, insulin resistance and late stage insulin dependency.

Similar Private Companies By Industry

Company Name Region
Jubilant Clinsys, Inc. United States
E-TrolZ, Inc. United States
Irvine Pharmaceutical Services, Inc. United States
Quantitative Technologies, Inc. United States
Proteovations, LLC United States

Recent Private Companies Transactions

February 12, 2015
Molecular Response, LLC, PDX Business Unit

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Crown Bioscience, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at